2025-11-06 - Analysis Report
Okay, here's an analysis of UNH (UnitedHealth Group Inc.) based on the provided data, presented as a report in English with numerical highlights and analysis.

**Report: UNH (UnitedHealth Group Inc.) Analysis**

**Company Overview:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services.

**1. Performance Relative to S&P 500 (VOO):**

*   **UNH Cumulative Return:** -18.31%
*   **VOO Cumulative Return:** 99.52%
*   **Absolute Divergence:** -121.0
*   **Relative Divergence:** 5.8 (on a scale where 0 is the minimum divergence and 100 is the maximum divergence)

**Analysis:** UNH has significantly underperformed the S&P 500 (VOO). The relative divergence of 5.8 indicates that this underperformance is near the lowest end of its historical range relative to the S&P 500.  This suggests a substantial deviation from the broader market's performance.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta | Cap(B) |
| :----------- | :------ | :------ | :------ | :--- | :------- |
| 2015-2017  | 58.0%   | 66.4% | 30.0%   | 0.1  | 199.7  |
| 2016-2018  | 41.0%   | 70.4% | 26.0%   | 0.1  | 225.7  |
| 2017-2019  | 36.0%   | 73.8% | 14.0%   | 0.2  | 266.3  |
| 2018-2020  | -43.0%  | 81.2% | -67.0%  | 0.5  | 317.7  |
| 2019-2021  | 16.0%   | 81.2% | -30.0%  | 1.5  | 454.9  |
| 2020-2022  | -1.0%   | 81.2% | 0.0%    | 1.5  | 480.3  |
| 2021-2023  | 24.0%   | 80.8% | 23.0%   | 0.4  | 476.9  |
| 2022-2024  | -27.0%  | 78.8% | -47.0%  | 0.3  | 458.2  |
| 2023-2025  | -61.0%  | 79.8% | -125.0% | 1.2  | 296.4  |

**Analysis:**

*   **CAGR:** Fluctuates significantly, with some periods showing strong growth and others substantial declines.
*   **MDD:** High Maximum Drawdown (MDD) values indicate significant volatility and potential for large losses.
*   **Alpha:** Alpha is inconsistent. Negative Alpha values suggest underperformance relative to a benchmark.
*   **Beta:** Beta values vary, indicating fluctuating sensitivity to market movements. Higher Beta values in more recent periods (e.g., 2019-2022) suggest increased correlation with the market.

**2. Recent Price Action:**

*   **Current Price:** 327.2
*   **Last Market Data:**
    *   Price: 327.21
    *   Previous Close: 330.83
    *   Change: -1.09
*   **5-Day Moving Average:** 340.51
*   **20-Day Moving Average:** 355.79
*   **60-Day Moving Average:** 335.64

**Analysis:** The stock price is below all three moving averages (5-day, 20-day, and 60-day), indicating a potential downtrend. The negative change from the previous close (-1.09) reinforces this downward momentum.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 22.86 (Oversold)
*   **PPO:** -1.42
*   **Hybrid Signal:** Cash_79%_Sell 79.7% of holdings (243 shares - Risky - MRI:0.50) (Cash Ratio: 79% on 2025-10-16)
*   **20-Day Relative Divergence Change:** -3.2 (Negative - Short-Term Decline)
*   **Expected Return (%):** -258.8

**Analysis:**

*   The **RSI** is in oversold territory (below 30), which *could* suggest a potential for a short-term bounce, but given the other indicators, it should be viewed with caution.
*   The negative **PPO** confirms the downtrend.
*   The **Hybrid Signal** recommends selling a significant portion of holdings and increasing the cash position, indicating a bearish outlook.  The MRI value associated with the Hybrid Signal is 0.50, indicating a risky situation, which conflicts with the overall MRI of 0.9. This conflict requires further investigation.
*   The negative change in **relative divergence** suggests continued short-term underperformance.
*   The extremely negative **expected return** indicates a very pessimistic outlook, suggesting significant underperformance compared to the S&P 500 over the long term.
* The `{'price': 327.21, 'previousClose': 330.83, 'change': -1.09}` shows a recent price drop, although not drastic, it contributes to the negative sentiment.

**4. Recent News & Significant Events:**

*   **Valuation Exploration:** The 10% share price drop is prompting valuation reassessments.
*   **Investment Compellingness:** Debates are ongoing regarding whether UNH represents a compelling investment opportunity.
*   **Regulatory Headlines:** A 33.8% drop may signal opportunity after recent regulatory headlines.

**Analysis:** Recent news highlights concerns about valuation following a significant price drop, possibly related to regulatory issues. Analyst perspectives on whether this presents a buying opportunity are mixed.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.00)
*   **Target Price:** Average: 385.40, High: 440.00, Low: 198.00

**Analysis:** Despite the recent negative performance, the analyst consensus remains a "Buy" with a significant upside potential based on the average target price. However, the wide range between the high and low target prices suggests considerable uncertainty.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
| :----------- | :--- | :------------- |
| 2025-10-28 | 2.59 | 113.16 B$ |
| 2025-08-11 | 3.76 | 111.62 B$ |
| 2025-05-07 | 6.9  | 109.58 B$ |
| 2024-11-04 | 6.56 | 100.82 B$ |
| 2025-10-28 | 6.56 | 100.82 B$ |

**Analysis:** Revenue has generally been increasing over the reported quarters. However, there's a significant drop in EPS in the most recent quarter (2025-10-28), which may be contributing to the negative sentiment.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue      | Profit Margin |
| :------------- | :----------- | :------------ |
| 2025-06-30 | $111.62B | 17.93%       |
| 2025-03-31 | $109.58B | 21.70%       |
| 2024-12-31 | $100.81B | 21.14%       |
| 2024-09-30 | $100.82B | 22.84%       |
| 2024-06-30 | $98.86B | 22.31%       |

**Capital and Profitability:**

| Quarter      | Equity      | ROE   |
| :------------- | :----------- | :---- |
| 2025-06-30 | $94.72B | 3.60% |
| 2025-03-31 | $95.04B | 6.62% |
| 2024-12-31 | $92.66B | 5.98% |
| 2024-09-30 | $94.53B | 6.41% |
| 2024-06-30 | $89.36B | 4.72% |

**Analysis:**

*   Revenue has been steadily increasing.
*   Profit margins have decreased in the most recent quarter.
*   ROE has decreased significantly in the most recent quarter, indicating lower profitability relative to equity.

**7. Overall Summary:**

UNH is currently facing significant headwinds. The stock has substantially underperformed the S&P 500, and recent technical indicators suggest a continued downtrend. A sharp decline in EPS, reduced profit margins, and decreased ROE are concerning. News headlines point to valuation concerns and potential regulatory pressures. While analyst consensus remains a "Buy," the wide range of target prices reflects considerable uncertainty. The MRI gives conflicting signals, requiring caution.

**Recommendation:** Based on the current data, a cautious approach is warranted. While the oversold RSI and analyst "Buy" ratings might suggest a potential for a rebound, the negative trends in profitability, underperformance relative to the market, and concerning news headlines indicate significant risks. Further investigation into the reasons behind the EPS decline and the potential impact of regulatory issues is crucial before considering a long position. A neutral to bearish stance seems appropriate at this time.
